BriaCell Book Value Per Share from 2010 to 2024

BCTXW Stock

USD 0.34 0.03 9.68%

BriaCell Therapeutics Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2024. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of BriaCell Therapeutics Corp according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

(0.28)

Current Value

(0.26)

Quarterly Volatility

57.15106351

Credit Downgrade

Yuan Drop

Covid

Check BriaCell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BriaCell Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.4 K, Interest Expense of 0.0 or Other Operating Expenses of 35 M, as well as many indicators such as Price To Sales Ratio of 0.0, Days Sales Outstanding of 0.0 or Invested Capital of 622.1 K. BriaCell financial statements analysis is a perfect complement when working with BriaCell Therapeutics Valuation or Volatility modules.

Check out the analysis of BriaCell Therapeutics Correlation against competitors.

Latest BriaCell Therapeutics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of BriaCell Therapeutics Corp over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. BriaCell Therapeutics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BriaCell Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (0.13) X

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

BriaCell Book Value Per Share Regression Statistics

	Arithmetic Mean	26.01
	Coefficient Of Variation	219.74
	Mean Deviation	38.62
	Median	2.21
	Standard Deviation	57.15
	Sample Variance	3,266
	Range	175
	R-Value	(0.60)
	Mean Square Error	2,235
	R-Squared	0.36
	Significance	0.02
	Slope	(7.72)
	Total Sum of Squares	45,727

BriaCell Book Value Per Share History

	2024	-0.26
	2023	-0.28
	2022	-0.24
	2021	0.67
	2020	3.75
	2019	-4.61
	2018	-1.11

Other Fundumenentals of BriaCell Therapeutics

Tangible Book Value Per Share

BriaCell Therapeutics Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Net Receivables	Intangible Assets	Current Deferred Revenue	Net Invested Capital	Long Term Investments	Net Working Capital	Long Term Debt	Short Long Term Debt	Capital Stock	Short Term Debt	Common Stock
Total Assets		0.79	-0.98	-0.33	-0.01	0.52	0.98	0.02	0.42	-0.44	0.79	-0.08	0.97	-0.56	-0.51	0.69	-0.51	0.69
Total Stockholder Equity	0.79		-0.8	0.18	-0.2	-0.1	0.77	-0.26	0.17	-0.13	0.98	-0.2	0.78	-0.2	-0.17	0.24	-0.17	0.24
Net Debt	-0.98	-0.8		0.24	0.11	-0.49	-1.0	0.09	-0.43	0.42	-0.83	0.17	-0.99	0.54	0.49	-0.63	0.49	-0.63
Retained Earnings	-0.33	0.18	0.24		-0.79	-0.7	-0.3	-0.86	-0.52	0.65	0.13	-0.71	-0.2	0.78	0.74	-0.88	0.74	-0.88
Accounts Payable	-0.01	-0.2	0.11	-0.79		0.13	-0.07	0.97	0.27	-0.42	-0.17	0.99	-0.19	-0.52	-0.5	0.58	-0.5	0.58
Total Liab	0.52	-0.1	-0.49	-0.7	0.13		0.54	0.27	0.42	-0.48	-0.07	0.03	0.51	-0.58	-0.54	0.74	-0.54	0.74
Total Current Assets	0.98	0.77	-1.0	-0.3	-0.07	0.54		-0.04	0.45	-0.45	0.8	-0.14	0.99	-0.57	-0.52	0.68	-0.52	0.68
Net Receivables	0.02	-0.26	0.09	-0.86	0.97	0.27	-0.04		0.3	-0.45	-0.23	0.93	-0.15	-0.56	-0.53	0.65	-0.53	0.65
Intangible Assets	0.42	0.17	-0.43	-0.52	0.27	0.42	0.45	0.3		-0.98	0.26	0.23	0.38	-0.79	-0.8	0.57	-0.8	0.57
Current Deferred Revenue	-0.44	-0.13	0.42	0.65	-0.42	-0.48	-0.45	-0.45	-0.98		-0.21	-0.37	-0.37	0.87	0.88	-0.67	0.88	-0.67
Net Invested Capital	0.79	0.98	-0.83	0.13	-0.17	-0.07	0.8	-0.23	0.26	-0.21		-0.18	0.81	-0.26	-0.23	0.29	-0.23	0.29
Long Term Investments	-0.08	-0.2	0.17	-0.71	0.99	0.03	-0.14	0.93	0.23	-0.37	-0.18		-0.25	-0.46	-0.45	0.5	-0.45	0.5
Net Working Capital	0.97	0.78	-0.99	-0.2	-0.19	0.51	0.99	-0.15	0.38	-0.37	0.81	-0.25		-0.47	-0.42	0.59	-0.42	0.59
Long Term Debt	-0.56	-0.2	0.54	0.78	-0.52	-0.58	-0.57	-0.56	-0.79	0.87	-0.26	-0.46	-0.47		1.0	-0.83	1.0	-0.83
Short Long Term Debt	-0.51	-0.17	0.49	0.74	-0.5	-0.54	-0.52	-0.53	-0.8	0.88	-0.23	-0.45	-0.42	1.0		-0.78	1.0	-0.78
Capital Stock	0.69	0.24	-0.63	-0.88	0.58	0.74	0.68	0.65	0.57	-0.67	0.29	0.5	0.59	-0.83	-0.78		-0.78	1.0
Short Term Debt	-0.51	-0.17	0.49	0.74	-0.5	-0.54	-0.52	-0.53	-0.8	0.88	-0.23	-0.45	-0.42	1.0	1.0	-0.78		-0.78
Common Stock	0.69	0.24	-0.63	-0.88	0.58	0.74	0.68	0.65	0.57	-0.67	0.29	0.5	0.59	-0.83	-0.78	1.0	-0.78

Click cells to compare fundamentals

About BriaCell Therapeutics Financial Statements

BriaCell Therapeutics investors use historical fundamental indicators, such as BriaCell Therapeutics' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in BriaCell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	(0.28)	(0.26)
Tangible Book Value Per Share	(0.29)	(0.28)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for BriaCell Stock Analysis

When running BriaCell Therapeutics' price analysis, check to measure BriaCell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BriaCell Therapeutics is operating at the current time. Most of BriaCell Therapeutics' value examination focuses on studying past and present price action to predict the probability of BriaCell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BriaCell Therapeutics' price. Additionally, you may evaluate how the addition of BriaCell Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC